Leeds hospitals involved in new coronavirus vaccine trial for pregnant women
It is aiming to recruit over 600 mums-to-be nationwide, to determine the best gap between doses
Last updated 3rd Aug 2021
A new study is being launched to determine what the best gap is between coronavirus vaccine doses for pregnant women, with scientists hoping findings will reassure expectant mothers on the safety of the jabs.
Researchers are aiming to recruit more than 600 pregnant women for the trial, which will monitor the vaccine’s effectiveness and follow the development of children up to one year old.
The launch comes less than a week after research revealed the vast majority of pregnant women admitted to hospital with Covid-19 are unvaccinated.
England’s chief midwife has written to GPs and fellow midwives across the country urging them to encourage expectant mothers to get a jab.
Those behind this latest Preg-CoV trial said while there are currently no safety concerns when it comes to pregnant women having Covid-19 jabs, they hope it will give expectant mothers and those caring for them “the highest quality of data about these vaccines”.
Almost 52,000 pregnant women in England have been vaccinated to date – with no safety concerns reported.
The trial – the UK’s largest investigating the best gap between first and second doses for pregnant women – involves £7.5 million of Government funding and is being led by St George’s, University of London.
It involves 13 hospital trusts across the UK, including Leeds Teaching Hospitals, Kate Robinson, the senior research midwife said:
"The most risk to a pregnant women is in her 3rd trimester, previous research has told us that. What we are worried about is that the current interval length is 8-12 weeks, so really because women are at most risk in their 3rd trimester, we want them to have had both vaccines by then.
"If we are waiting 8-12 weeks they actually might have delivered by then. So this study is looking at doing 4-6 weeks or 8-12 weeks and then we can have a look at which ones better."
How will the trial work?
Vaccines involved initially will be the Pfizer/BioNTech and the Moderna vaccine but other new vaccines will be included as they are approved in the future.
Women aged 18 to 44 will be recruited from some 15 sites across England if they are between 13 and 34 weeks gestation at the time of vaccination.
They will randomly receive one of the vaccines either at a four to six week dosing gap or the longer eight to 12 week dosing gap.
The first trial results, looking at any adverse events following a first dose, should be available towards the end of the year, while immune response results are expected in the first quarter of next year.
Dr Pat O’Brien, vice president at the Royal College of Obstetricians and Gynaecologists, said the findings of the study are likely to be relevant “for many years to come”.
He said: “This is an important study. We feel comfortable with the safety of these vaccines. What we want to understand now is how to fine-tune them, to understand better how they work. What’s the optimal way of giving them?
“Do they work as well in pregnant women as in other people? Bear in mind this pandemic is likely to become endemic, this is likely to be ongoing. So I suspect that the findings from this trial will be relevant to us, to pregnant women for many years to come".
Vaccines minister Nadhim Zahawi said: “Pregnant women are more likely to get seriously ill from Covid-19 and we know that vaccines are safe for them and make a huge difference – in fact no pregnant woman with two jabs has required hospitalisation with Covid-19.
“This Government-backed trial will provide more data about how we can best protect pregnant women and their babies, and we can use this evidence to inform future vaccination programmes.
“I encourage anyone who is pregnant and eligible to sign up and contribute to research that will save lives for years to come".
Last week researchers at Oxford University described findings of their work as “concerning”, saying that one in 10 pregnant women admitted to hospital with symptoms of Covid-19 often require intensive care.
Marian Knight, professor of maternal and child population health at the Nuffield Department of Population Health, University of Oxford, and chief investigator of the study, said pregnant women can be “reassured” about the safety of the vaccines and that antibodies will be passed to their babies.